Compare Progressive Corp (PGR) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Progressive Corp vs Spyre Therapeutics Inc. Common Stock — how do they compare? Progressive Corp trades at $215.59 (market cap $129.36B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Progressive Corp is far larger — about 17.2× Spyre Therapeutics Inc. Common Stock's market cap, and Progressive Corp pays a 0.18% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Progressive Corp for 81 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| PGR | SYRE | |
|---|---|---|
Market Cap | $129.36B | $7.52B |
Volume | 3,501,619 | 1,441,031 |
Sector | Financials | Health |
52-Week High | $236.18 | $108.92 |
52-Week Low | $190.40 | $22.18 |
Typical Hold Time | 81 Days | 0 Days |
Enterprise Value | $137.57B | $6.52B |
Dividend Yield | 0.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PGR trades at $213.46, down 3.1% on the day, amid mixed earnings results with recent Q3 2026 miss. The stock shows strong fundamentals with revenue growth from $49.6B in 2022 to $87.6B in 2025 and net income margin of 12.85%. Technicals are bullish with moving averages supporting upside, while RSI levels indicate potential overbought conditions. Recent news highlights Progressive's telematics edge and inclusion in dividend-focused articles.
Outlook remains positive with analyst consensus target of $222.23 implying ~4% upside. Key opportunities include sustained underwriting strength and dividend reliability, but risks involve competitive pressures in auto insurance and earnings volatility. The stock's valuation at P/E of 11.18 appears reasonable relative to profitability metrics.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Progressive Corp
Progressive underwrites private and commercial auto insurance and specialty lines
Read more on PGR →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
